Actively Recruiting

Age: 2Years +
All Genders
NCT06514560

OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients

Led by Institute of Tropical Medicine, Belgium · Updated on 2024-07-23

80

Participants Needed

1

Research Sites

132 weeks

Total Duration

On this page

Sponsors

I

Institute of Tropical Medicine, Belgium

Lead Sponsor

A

Alert Hospital, Ethiopia

Collaborating Sponsor

AI-Summary

What this Trial Is About

While there are indications that 28 days of miltefosine is not sufficient for treating CL by L. aethiopica, a better understanding of what happens in terms of parasite clearance and drug dosing is lacking. In this study, longitudinal measurements of parasite and drug concentrations during treatment are done to monitor parasite kinetics as well as pharmacokinetics. This data will be crucial to provide more information on duration and dosing of miltefosine in CL patients globally, and in Ethiopia and pediatric patients in particular.

CONDITIONS

Official Title

OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients

Who Can Participate

Age: 2Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical or parasitological (microscopy or PCR) confirmation of leishmaniasis
  • Age over 2 years
  • Clinical decision to start miltefosine treatment as systemic treatment
  • Females of child-bearing age willing to use contraceptives for 6 months (parenteral, IUD, or implant)
  • Willing and able to provide informed consent
  • Willing to be hospitalized for the duration of treatment
Not Eligible

You will not qualify if you...

  • Currently on treatment or received modern treatment for leishmaniasis in the last 3 months
  • Pregnant or breastfeeding
  • Unlikely to attend follow-up visits
  • Abnormal laboratory values: Hemoglobin less than 5.0 g/100mL, Platelets less than 50 x 10^9/L, White blood count less than 1 x 10^9/L, ASAT/ALAT greater than 3 times upper normal limit, Creatinine above normal limit

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Africa Leprosy, Tuberculosis, Rehabilitation and Training (ALERT) Hospital

Addis Ababa, Ethiopia

Actively Recruiting

Loading map...

Research Team

S

Shimelis Nigusse, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here